Chemed Corporation Q3 2025 Earnings Release

Chemed Corporation reported its financial results for the third quarter ended September 30, 2025. The company announced a 3.1% increase in revenue to $624.9 million compared to the prior-year period. However, GAAP Diluted Earnings-per-Share (EPS) decreased by 10.8% to $4.46, and Adjusted Diluted EPS declined by 6.6% to $5.27. The VITAS segment saw a 4.2% increase in net patient revenue to $407.7 million, while the Roto-Rooter segment reported a 1.1% revenue increase to $217.2 million. Chemed also repurchased 407,500 shares of its stock for $180.8 million during the quarter. The company reiterated its full-year 2025 guidance, expecting EPS in the range of $22.00 to $22.30, excluding certain non-cash expenses and discrete items.